Nama Insights

LB Pharmaceuticals (LBRX)

Healthcare · Biotechnology · NASDAQ

LB Pharmaceuticals (LBRX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.30B and a free-cash-flow yield of -10.9%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 2.7/10
Clearly negative, short of the bottom band. As of Nov 20, 2026.
Momentum
Leading · +148.4% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-22.6%
How far the last close sits under the highest price of the past five years.
Market cap$1.30B
Trailing P/E—
Price / book3.1
Price / sales—
FCF yield-10.9%
Dividend yield—
Gross margin0.0%
Operating margin0.0%
Net margin0.0%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta—
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

LBRX earnings

Next report: Mar 25, 2027 (Q4 2026, EPS estimate -$1.84). Beat the EPS estimate in 0 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 5, 2026 -$1.79 -$1.60 -11.9% $0
Q2 2026 Aug 11, 2026 -$1.71 -$0.80 -113.8% $0
Q4 2025 Mar 26, 2026 -$0.45 -$0.32 -40.6% $0
Q3 2025 Nov 6, 2025 -$0.61 -$0.28 -117.9% $0

LBRX analyst price target

Median target $55.00 from 11 analysts, ranging $35.00 – $80.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live LBRX data on Nama Insights →

LBRX FAQ

Is LBRX a buy?
Nama's AI scorecard currently rates LB Pharmaceuticals Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does LBRX report earnings?
LB Pharmaceuticals's next scheduled report is on Mar 25, 2027. Analysts expect EPS of -$1.84.
What is the LBRX price target?
The median analyst price target from 11 analysts is $55.00, with a range of $35.00 – $80.00.
Is LBRX Shariah compliant?
Nama's AAOIFI-style screen reads LB Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.